血清3种肿瘤标志物检测在卵巢肿瘤诊断与临床分期中的应用

摘要

目的：研究和评价HE4、CA125和PDGF-BB三种血清肿瘤标志物在恶性卵巢肿瘤诊断、临床分期和治疗中的应用价值。方法选择2012年6月22日~2014年10月28日扬州市苏北人民医院、扬州市第一人民医院收治的卵巢包块患者216例（均行手术等治疗），其中未绝经组恶性卵巢肿瘤26例、良性卵巢肿瘤53例及60例健康女性（对照组）；绝经组恶性卵巢肿瘤50例、良性卵巢肿瘤87例及108例健康女性（对照组）。同期选择在该院体检中心经体检合格的健康女性168例作为对照组，利用免疫化学发光法和ELISA法检测未绝经组和绝经组中患者血清HE4、CA125和PDGF-BB含量，并对比分析三者在恶性卵巢肿瘤的诊断和临床分期中的应用价值。结果恶性卵巢肿瘤患者（包括未绝经组和绝经组）的HE4、CA125和PDGF-BB血清水平均明显高于正常对照组和良性卵巢肿瘤（P均＜0.01）。Spearman相关分析显示相关性具有统计学意义，且HE4的相关性最高（r=0.613)。HE4和CA125的敏感度优于PDGF-BB，差异有统计学意义（均P0.05). At the same time, the specificity and accuracy of HE4 reached88.1% and87.1%, respectively when the level of36.5pmol/L was taken as the threshold value in premenopausal group. In the menopausal group, however, the specificity and accuracy were found to be93.5% and88.7% respectively if the cut-off value of56.8pmol/L was used.Conclusion Mornitoring of the three seral tumor markers of serum HE4, CA125 and PDGF-BB possesses a practical significance in helping to master the situation of patients, efficacy of treatments, and assessment of prognosis of malignant ovarian tumors.